Koken Licenses Alnylam's RNAi Patents for Research Uses | GenomeWeb

NEW YORK (GenomeWeb News) – Tokyo-based Koken has acquired the rights to use Alnylam Pharmaceuticals' RNAi-related patents under a non-exclusive, worldwide agreement, Alnylam said today.

Koken will use the patents from Alnylam's Kreutzer Limmer patent family, which covers aspects of the structure and functional properties of synthetic RNAi products, to manufacture and offer siRNA reagents to industry and academic researchers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.